A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer.

Trial Profile

A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs MKC 1 (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 24 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 02 Jul 2008 Status changed from recruiting to in progress as stated on the EntreMed website.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top